Investors

Press Releases

Press Releases

Press Releases

January 6, 2021
– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta ® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million – STOUGHTON, Mass. , Jan.